Marker Therapeutics
MRKR
33 hedge funds and large institutions have $49.5M invested in Marker Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
773% more capital invested
Capital invested by funds: $5.67M → $49.5M (+$43.8M)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
19.23% more ownership
Funds ownership: 22.54% → 41.77% (+19%)
18% more funds holding
Funds holding: 28 → 33 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.24M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.96M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.96M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.17M |
| 5 |
LPL Financial
San Diego,
California
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$53.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$36.8K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$15.5K |
| 4 |
Morgan Stanley
New York
|
-$10.8K |
| 5 |
BlackRock
New York
|
-$8.66K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $722 | – | – | – |
|
|
SS
27
SBI Securities
Tokyo,
Japan
| $628 | +$715 | +202 | New |
|
28
Group One Trading
Chicago,
Illinois
| $554 | – | – | – |
|
|
HNB
29
Hilltop National Bank
Casper,
Wyoming
| $227 | – | – | – |
|
30
JP Morgan Chase
New York
| $119 | – | – | – |
|
31
BNP Paribas Financial Markets
Paris,
France
| $72 | +$81 | +23 | New |
|
|
VCM
32
Versant Capital Management
Phoenix,
Arizona
| $47 | – | – | – |
|
33
Fidelity Investments
Boston,
Massachusetts
| $37 | – | – | – |
|
|
34
UBS Group
Zurich,
Switzerland
| – | -$53.9K | -19,104 | Closed |
|
|
35
Citadel Advisors
Miami,
Florida
| – | -$36.8K | -13,032 | Closed |
|
|
ACM
36
ADAR1 Capital Management
Austin,
Texas
| – | -$6.86K | -2,432 | Closed |
|
MRKR Hedge Fund Activity: Q4 2024 in Review
33 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2024, worth a combined $49.5M — up 773% from $5.67M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MRKR positions and 3 closed out — a net gain of 5 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $3.24M. The largest seller was UBS Group, exiting entirely with an estimated $53.9K sold.
- 33 institutional investors held Marker Therapeutics (MRKR) as of Q4 2024, up from 28 in Q3 2024.
- Funds reported $49.5M of Marker Therapeutics stock for Q4 2024, up 773% quarter-over-quarter.
- 8 funds opened new Marker Therapeutics positions in Q4 2024 and 3 closed out, a net change of +5 holders.
- The largest Marker Therapeutics buyer in Q4 2024 was Alyeska Investment Group, an estimated $3.24M added.
- The largest Marker Therapeutics seller in Q4 2024 was UBS Group, an estimated $53.9K sold.
Based on aggregated 13F filings for Q4 2024.